5205-11-8 Usage
Description
BENZOIC ACID 3-METHYL-2-BUTENYL ESTER is an organic compound that is derived from benzoic acid and 3-methyl-2-butenyl alcohol. It is a colorless, clear liquid with a balsam, fruity, chocolate, and ylang aroma. This ester is characterized by its medium strength odor and balsamic type, making it a valuable component in the fragrance industry.
Uses
Used in Fragrance Industry:
BENZOIC ACID 3-METHYL-2-BUTENYL ESTER is used as a fragrance ingredient for its unique and pleasant aroma. Its balsam, fruity, chocolate, and ylang scent profile makes it suitable for creating various fragrances in the perfume and cosmetic industry.
Used in Flavor Industry:
In addition to its application in the fragrance industry, BENZOIC ACID 3-METHYL-2-BUTENYL ESTER is also used as a flavoring agent. Its distinct taste and aroma contribute to the enhancement of flavors in the food and beverage industry, particularly in products that require a balsamic, fruity, or chocolate note.
Used in Aromatherapy:
Due to its pleasant and soothing aroma, BENZOIC ACID 3-METHYL-2-BUTENYL ESTER can be used in aromatherapy applications. It can be incorporated into essential oil blends or used in diffusers to create a calming and relaxing atmosphere, promoting mental well-being and stress relief.
Used in the Production of Cascarilla Bark Oil:
BENZOIC ACID 3-METHYL-2-BUTENYL ESTER is reported to be used in the production of Cascarilla bark oil, which is derived from the bark of the Croton eluteria plant. This oil is known for its medicinal properties and is used in traditional remedies, particularly for digestive issues.
Used in the Production of Ylang Ylang Oil:
This ester is also used in the production of ylang ylang oil, which is extracted from the flowers of the Cananga odorata tree. Ylang ylang oil is widely used in the perfume industry for its rich, floral, and slightly fruity scent. It is also used in aromatherapy for its calming and mood-enhancing properties.
Check Digit Verification of cas no
The CAS Registry Mumber 5205-11-8 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,2,0 and 5 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 5205-11:
(6*5)+(5*2)+(4*0)+(3*5)+(2*1)+(1*1)=58
58 % 10 = 8
So 5205-11-8 is a valid CAS Registry Number.
InChI:InChI=1/C12H14O2/c1-10(2)8-9-14-12(13)11-6-4-3-5-7-11/h3-8H,9H2,1-2H3
5205-11-8Relevant articles and documents
Base-Promoted Radical Azofluoromethylation of Unactivated Alkenes
Lu, Zhichao,Hennis, Olivia,Gentry, Joseph,Xu, Bo,Hammond, Gerald B.
supporting information, p. 4383 - 4388 (2020/06/04)
The base-induced reaction of aryl diazonium salts with commercially available CF3SO2Na/CF2HSO2Na allows for the generation of the corresponding diazene radicals along with fluoromethyl radicals. The addition of fluoromethyl radicals to alkenes with subsequent diazene trapping provides the azofluoromethylation products in good to excellent yields. This metal-free method under mild reaction conditions has broad functional group compatibility and is applicable in the late-stage modification of various natural products and bioactive molecules.
Epoxide as precatalyst for metal-free catalytic transesterification
Tanaka, Shinji,Nakashima, Takuya,Satou,Oono, Hiromi,Kon, Yoshihiro,Tamura, Masanori,Sato, Kazuhiko
, p. 2009 - 2013 (2019/07/03)
Transesterification of methyl esters was accelerated by an in situ-generated metal-free catalyst comprising a quaternary alkylammonium salt and an epoxide. The combination of a quaternary alkylammonium acetate and glycidol is optimal, and various esters were synthesized from methyl esters with alcohols in good to excellent yield. Analysis of the catalyst solution revealed that basic species are generated by the ring-opening reaction of epoxide.
ANTIDIABETIC TRICYCLIC COMPOUNDS
-
Page/Page column 93; 94, (2015/04/28)
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
